NCT00048061 - MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis | Biotech Hunter

Enrollment

1,609

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Post Menopausal Osteoporosis

Interventions

DRUG

Ibandronate [Bonviva/Boniva]

2.5mg po daily

DRUG

Ibandronate [Bonviva/Boniva]

100mg po monthly on a single day

DRUG

Ibandronate [Bonviva/Boniva]

100mg po monthly over 2 consecutive days

DRUG

Ibandronate [Bonviva/Boniva]

150mg po monthly

DIETARY_SUPPLEMENT

Calcium

500 mg/day

DIETARY_SUPPLEMENT

Vitamin D

400 IU/day

Trial Locations (68)

1036

Budapest

1083

Budapest

2170

Merksem

2196

Johannesburg

2750

Ballerup Municipality

3052

Parkville

4010

Stavanger

4020

Liège

5000

Adelaide

5035

Adelaide

5507

Haugesund

6400

Kiskunhalas

6979

Perth

7100

Vejle

7500

Cape Town

8091

Zurich

8230

Balatonfüred

8900

Zalaegerszeg

9000

Aalborg

12200

Berlin

14033

Caen

19610

Wyomissing

20817

Bethesda

20902

Wheaton

23294

Richmond

28041

Madrid

30167

Hanover

32607

Gainesville

37000

León

37067

Valeggio sul Mincio

53100

Siena

53792

Madison

59120

Billings

63110

St Louis

68131

Omaha

69437

Lyon

78229

San Antonio

80227

Lakewood

85100

Obregón

87106

Albuquerque

90211

Los Angeles

92270

Rancho Mirage

92357

Loma Linda

92618

Irvine

94612

Oakland

97213

Portland

98144

Seattle

07039

Livingston

13077-005

Campinas

80060-240

Curitiba

90035-003

Porto Alegre

04026-000

São Paulo

T2N 4N1

Calgary

V5Z 2N6

Vancouver

M5S 1B2

Toronto

G1V 3M7

Québec

305 99

Pilsen

128 00

Prague

169 02

Prague

0176

Oslo

31-501

Krakow

04-730

Warsaw

011025

Bucharest

08907

Barcelona

CF64 2XX

Cardiff

L22 0LG

Liverpool

E11 1NR

London

SO16 6YD

Southampton

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY